In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed BRCA1/2-mutated advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond BRCA1/2 mutations, including combination strategies, and discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Journal of Hematology & Oncology Open Access 06 November 2021
-
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Hereditary Cancer in Clinical Practice Open Access 28 August 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
George, A., Kaye, S. & Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol. 14, 284–296 (2017).
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381–1388 (2013).
González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).
Coleman, R. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403–2415 (2019).
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
Matthews, C. A. et al. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a in BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. J. Clin. Oncol. 37 (Suppl. 15), 5541 (2019).
Oaknin, A. et al. Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial. Ann. Oncol. 30 (Suppl. 5), mdz250.003 (2019).
Acknowledgements
The authors acknowledge the National Institute for Health Research, Royal Marsden and ICR Biomedical Research Centre for Cancer. The work of C.J.L. is funded by Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre (CTR-Q4-Y2) and by a Cancer Research UK Programme Grant (CRUK/A14276).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.B. has received honoraria as an advisory board member and/or giving lectures for AstraZeneca, Clovis, Genmabs, Merck Serono, Pharmamar, Roche, Seattle Genetics and Tesaro/GSK. C.J.L. has received research funding from Artios, AstraZeneca and Merck KGaA; has received honoraria as a consultant or senior advisory board for Artios, AstraZeneca, Gerson Lehrman Group, Merck KGaA, Ono Pharma, Sun Pharma, Syncona, Tango, Third Rock and Vertex; owns stock in Ovibio and Tango; and is a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR Rewards to Inventors scheme.
Supplementary information
Rights and permissions
About this article
Cite this article
Banerjee, S.N., Lord, C.J. First-line PARP inhibition in ovarian cancer — standard of care for all?. Nat Rev Clin Oncol 17, 136–137 (2020). https://doi.org/10.1038/s41571-020-0335-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-0335-9
This article is cited by
-
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Hereditary Cancer in Clinical Practice (2021)
-
Emerging strategies for treating metastasis
Nature Cancer (2021)
-
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Journal of Hematology & Oncology (2021)